文献速递银屑病与炎症性皮肤病

利生奇珠单抗与富马酸酯在系统治疗初治中重度斑块状银屑病患者中的患者报告结局:一项3期临床试验

Patient-reported outcomes with risankizumab versus fumaric acid esters in systemic therapy-naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2021-07-12

这项3期临床试验将系统治疗初治的中重度斑块状银屑病患者随机分配接受利生奇珠单抗或富马酸酯治疗,评估患者报告结局。结果显示利生奇珠单抗在症状、生活质量、焦虑抑郁及患者整体评估等多个维度均显著优于富马酸酯。

要点

  • 利生奇珠单抗在PSS总分及发红、瘙痒、灼烧评分上第16和24周均显著优于富马酸酯(P<0.001)。
  • DLQI评分利生奇珠单抗组显著更低,第16和24周最小二乘均值差分别为-7.4和-7.6(均P<0.001)。
  • SF-36、HADS、PtGA、EQ-5D-5L及PBI等多个患者报告结局均显著优于富马酸酯(P≤0.002或P<0.001)。

核心结论

  • 在系统治疗初治的中重度斑块状银屑病患者中,利生奇珠单抗较富马酸酯在多个维度的患者报告结局上带来显著获益。

主要发现

  • 第16和24周,利生奇珠单抗组PSS总分及发红、瘙痒、灼烧评分较富马酸酯组显著改善(P<0.001)。
  • 第16和24周,DLQI评分利生奇珠单抗组显著更低,最小二乘均值差分别为-7.4和-7.6(均P<0.001)。
  • 第16和24周,利生奇珠单抗组SF-36躯体与心理成分总结评分、HADS焦虑与抑郁评分、PtGA、EQ-5D-5L指数及视觉模拟量表评分改善均更大(均P≤0.002)。
  • 第16和24周,PBI利生奇珠单抗组显著更高,最小二乘均值差分别为1.1和1.3(均P<0.001)。

临床怎么用

  • 对于系统治疗初治的中重度斑块状银屑病患者,选择利生奇珠单抗可能较富马酸酯更有利于改善症状负担、生活质量及情绪状态。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In a phase 3 clinical study, patients from Germany with moderate to severe psoriasis who were naïve to systemic treatment and received risankizumab had greater and more rapid disease improvements compared with those who received fumaric acid esters (FAEs). OBJECTIVE: To evaluate patient-reported outcomes (PROs) in patients treated with risankizumab compared with FAEs. METHODS: Adult patients were randomized 1:1 to receive either risankizumab 150 mg subcutaneous injections at weeks 0, 4 and 16 or FAEs (Fumaderm® ) provided according to the prescribing label. PRO secondary endpoints assessed were Psoriasis Symptom Scale (PSS), Dermatology Life Quality Index (DLQI), 36-Item Short Form Health Survey, version 2 (SF-36v2), Patient Benefit Index (PBI), Hospital Anxiety and Depression Scale (HADS), Patient Global Assessment (PtGA) and European Quality of Life 5 Dimensions 5 Level (EQ-5D-5L). PROs were assessed at weeks 0, 16 and 24. RESULTS: Sixty patients each were randomized to receive risankizumab or FAEs. A significant PSS improvement was observed with risankizumab vs. FAEs at weeks 16 and 24 for total and psoriasis-associated redness, itching and burning scores (P < 0.001). DLQI scores were significantly lower (reflecting better health-related quality of life) with risankizumab vs. FAEs, with least squares (LS) mean differences of -7.4 and -7.6 at weeks 16 and 24, respectively (both P < 0.001). Patients randomized to risankizumab also had larger improvements in SF-36 Physical and Mental Component Summary scores, HADS anxiety and depression scores, PtGA, and EQ-5D-5L index and visual analogue scale scores (all P ≤ 0.002) at weeks 16 and 24 compared with FAEs. PBI was significantly higher, indicating greater benefit, with risankizumab vs. FAEs, with an LS mean difference of 1.1 and 1.3 at weeks 16 and 24, respectively (both P < 0.001). CONCLUSIONS: Risankizumab provides significant benefits over FAEs in improving PROs across several dimensions in patients with moderate to severe psoriasis.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Thaçi D, Soliman AM, Eyerich K, et al. Patient-reported outcomes with risankizumab versus fumaric acid esters in systemic therapy-naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial. J Eur Acad Dermatol Venereol. 2021. PMID: 33428281. doi:10.1111/jdv.17109

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。